Business News • PR NewsWire • Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™

Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™

Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™

SOUTH PLAINFIELD, N.J., April 15, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the pivotal FIREFISH trial demonstrated that infants with type 1 spinal muscular atrophy (SMA) treated with Evrysdi™ (risdiplam) obtained increases in...

View More : https://www.prnewswire.com:443/news-releases/continued-improvements-in-motor-milestones-in-infants-with-type-1-spinal-mu...

Releted News by prnewswire

Invitation to Kindred Group's presentation of the Interim report for the first quarter 2021

4. Ethnosport-Forum ist beendet

Mixed Tocopherol Market Procurement Intelligence Report With COVID-19 Impact Update| SpendEdge

Continued Improvements in Motor Milestones in Infants with Type 1 Spinal Muscular Atrophy After Two Years of Treatment with Evrysdi™

Fluidra expects to grow sales above 6% and increase dividend by 15% in the coming years

APTMetrics Launches Inclusive Leadership Solutions